These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26928674)

  • 41. Bone marrow stromal cells as targets for gene therapy of hemophilia A.
    Chuah MK; Brems H; Vanslembrouck V; Collen D; VandenDriessche T
    Hum Gene Ther; 1998 Feb; 9(3):353-65. PubMed ID: 9508053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
    Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL
    Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero.
    Chen XG; Zhu HZ; Gong JL; Li F; Xue JL
    Acta Pharmacol Sin; 2004 Jun; 25(6):789-93. PubMed ID: 15169633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Construction of mammary gland-specific expression vectors for human clotting factor IX and its secretory expression in goat milk.
    Zhang K; Lu D; Xue J; Huang Y; Huang S
    Chin J Biotechnol; 1997; 13(4):271-6. PubMed ID: 9631263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of a second intron on recombinant MFG retroviral vector.
    Malik AK; Wang JM; Kurachi K
    Arch Virol; 2001; 146(3):601-9. PubMed ID: 11338393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides.
    Hodges BL; Taylor KM; Joseph MF; Bourgeois SA; Scheule RK
    Mol Ther; 2004 Aug; 10(2):269-78. PubMed ID: 15294174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B.
    Coutu DL; Cuerquis J; El Ayoubi R; Forner KA; Roy R; François M; Griffith M; Lillicrap D; Yousefi AM; Blostein MD; Galipeau J
    Biomaterials; 2011 Jan; 32(1):295-305. PubMed ID: 20864158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Human coagulation factor IX gene therapy in murine hemophilia B by hydrodynamic delivery and site-specific genomic integration].
    Zhang L; Gu DS; DU WT; Liu PX; Lu SH; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):294-9. PubMed ID: 21122306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells.
    Dodd M; Marquez-Curtis L; Janowska-Wieczorek A; Hortelano G
    J Gene Med; 2014; 16(5-6):131-42. PubMed ID: 24947827
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The transfer and expression of human clotting factor IX in muscle mediated by electroporation].
    Wang H; Wang F; Chen L; Xue J; Lu D
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Dec; 18(6):476-8. PubMed ID: 11774220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
    Kim HS; Kim JC; Lee YK; Kim JS; Park YS
    J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimization of cis-acting elements for gene expression from nonviral vectors in vivo.
    Ehrhardt A; Peng PD; Xu H; Meuse L; Kay MA
    Hum Gene Ther; 2003 Feb; 14(3):215-25. PubMed ID: 12639302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene therapy and the hemophilias.
    Lozier JN; Brinkhous KM
    JAMA; 1994 Jan; 271(1):47-51. PubMed ID: 8258886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels.
    Wang JM; Zheng H; Blaivas M; Kurachi K
    Blood; 1997 Aug; 90(3):1075-82. PubMed ID: 9242538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of a bacterially expressed human factor IX light chain to develop polyclonal antibody anti-hFIX.
    Safari S; Zomorodipour A; Amirmozaffari N; Daliri Choopari M
    Appl Biochem Biotechnol; 2009 Nov; 159(2):404-14. PubMed ID: 19145409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-beta1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX.
    Gordon EM; Skotzko M; Kundu RK; Han B; Andrades J; Nimni M; Anderson WF; Hall FL
    Hum Gene Ther; 1997 Jul; 8(11):1385-94. PubMed ID: 9295133
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel gene expression system: non-viral gene transfer for hemophilia as model systems.
    Miao CH
    Adv Genet; 2005; 54():143-77. PubMed ID: 16096011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [High expression of human FIX(hFIX) in transgenic mice directed by goat beta-casein gene promoter].
    Huang Z; Yan JB; Huang Y; Sun Q; Xiao YP; Huang Y; Zeng YT
    Yi Chuan Xue Bao; 2002; 29(3):206-11. PubMed ID: 12182072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-viral human proGDNF gene delivery to rat bone marrow stromal cells under ex vivo conditions.
    Noori-Zadeh A; Mesbah-Namin SA; Tiraihi T; Rajabibazl M; Taheri T
    J Neurol Sci; 2014 Apr; 339(1-2):81-6. PubMed ID: 24518204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.